Ferroptosis Regulation in Cancer Metabolism

Cancer cells exploit a finely tuned balance between oxidant generation and antioxidant defences to sustain rapid growth. Ferroptosis is an iron-dependent form of regulated cell death driven by unchecked lipid peroxidation. In malignant cells, key metabolic nodes regulate ferroptotic sensitivity, chief among them the cystine/glutamate antiporter, redox-active enzymes and nutrient-sensing kinases. Uptake of cystine via SLC7A11 fuels glutathione synthesis, enabling glutathione peroxidase 4 (GPX4) to detoxify lipid hydroperoxides and prevent membrane damage. Conversely, disruption of cystine import or inhibition of GPX4 triggers lethal peroxidation cascades. Beyond this core axis, oncogenic signalling and epigenetic mechanisms modulate the expression of ferroptosis regulators, while metabolic pathways such as glutamine and glucose utilisation impose additional constraints. mTORC1 integrates amino acid availability with de novo GPX4 production, linking nutrient status to ferroptotic defence. Tumour heterogeneity in ferroptosis regulation underlies variable therapeutic responses, suggesting that targeting metabolic vulnerabilities could enhance the efficacy of conventional and emerging anticancer strategies. This interplay between iron chemistry, lipid peroxidation and metabolic control points to novel combination treatments that tip cancer cells towards ferroptotic demise while sparing normal tissues.

Research from Nature Portfolio

Recent studies have shown that the level of SLC7A11 expression dictates a context-dependent vulnerability to oxidative stress. Moderate transporter upregulation protects cells, whereas very high levels provoke intracellular cystine overload, NADPH depletion and cell death under peroxide challenge. This dual role refines understanding of SLC7A11 as both a pro-survival factor and a metabolic liability. In parallel, work has revealed that mTORC1 couples cyst(e)ine availability to GPX4 protein synthesis through the Rag-mTORC1-4EBP axis. Pharmacological inhibition of mTORC1 reduces GPX4 levels, sensitises tumour cells to ferroptosis inducers and synergises to suppress patient-derived xenograft growth. Together, these findings underscore the importance of transporter expression and nutrient-sensing kinases in orchestrating ferroptotic thresholds in cancer.

Ferroptosis Regulation in Cancer Metabolism publication trend

The graph below shows the total number of articles in ferroptosis regulation in cancer metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Ferroptosis: Iron-dependent regulated cell death characterised by accumulation of lipid hydroperoxides.

SLC7A11: Cystine/glutamate antiporter that imports cystine to support glutathione synthesis and antioxidant defence.

GPX4: Glutathione peroxidase that reduces lipid peroxides to non-toxic lipids, preventing ferroptosis.

Lipid peroxidation: Oxidative degradation of polyunsaturated fatty acids in membranes, leading to cell death.

mTORC1: Nutrient-sensing kinase complex that regulates protein synthesis, including GPX4, in response to amino acid availability.

References

1. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nature Communications (2023).
2. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nature Communications (2021).
3. Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis. Journal of Hematology & Oncology (2024).
4. A novel MYC-ZNF706-SLC7A11 regulatory circuit contributes to cancer progression and redox balance in human hepatocellular carcinoma. Cell Death & Differentiation (2024).